BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers

Company: CNS Pharmaceuticals Inc. (CNSP)
Category: Stock Spotlights

CNS Pharmaceuticals (NASDAQ: CNSP) is leading the charge toward advancing research on the treatment for glioblastoma multiforme (“GBM”) as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of its lead product candidate, Berubicin, for the treatment of GBM, dosing its first patients in September. A recent article discussing this reads, “CNS Pharmaceuticals expects to report an interim analysis of the trial when 30-50% of the planned subjects reach six months in-study, potentially in the first half of 2023. The adaptive, multicenter, open-label, randomized, and controlled study will involve about 243 adult patients with recurrent GBM after failure of standard first-line therapy. The subjects will be randomized in a 2:1 ratio to receive Berubicin or lomustine, a compound used in chemotherapy, to evaluate overall survival, the study’s primary endpoint. The study is expected to potentially build on the phase 1 trial and pharmacokinetic study of Berubicin, whose results revealed that 44% of the patients showed clinical response of stable disease or better, with one patient demonstrating a lack of detectable cancer cells and two patients with partial tumor reduction of up to 80%.

To view the full article, visit https://ibn.fm/FLko0

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050